메뉴 건너뛰기




Volumn 7, Issue 3, 2011, Pages 333-344

Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?

Author keywords

Cancer; Cardiotoxicity; Chemotherapy; Heart failure; Malignancy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EDETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; LAPATINIB; PACLITAXEL; PREDNISONE; RAZOXANE; TRASTUZUMAB; TROPONIN I; TROPONIN T; VINCRISTINE;

EID: 79960239852     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.03.005     Document Type: Review
Times cited : (20)

References (54)
  • 1
    • 0015990773 scopus 로고
    • A new anticancer drug with significant clinical activity
    • Blum R.H., Carter Adriamycin S.K. A new anticancer drug with significant clinical activity. Ann Intern Med 1974, 80:249-259.
    • (1974) Ann Intern Med , vol.80 , pp. 249-259
    • Blum, R.H.1    Carter Adriamycin, S.K.2
  • 2
    • 0015849162 scopus 로고
    • A clinicopathologic analysis of adriamycin cardiotoxicity
    • Lefrak E.A., Pitha J., Rosenheim S., et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
    • (1973) Cancer , vol.32 , pp. 302-314
    • Lefrak, E.A.1    Pitha, J.2    Rosenheim, S.3
  • 3
    • 0015643470 scopus 로고
    • Adriamycin-an antitumor antibiotic in the treatment of neoplastic diseases
    • Tan C., Etcubanas E., Wollner N., et al. Adriamycin-an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973, 32:9-17.
    • (1973) Cancer , vol.32 , pp. 9-17
    • Tan, C.1    Etcubanas, E.2    Wollner, N.3
  • 4
    • 0018716636 scopus 로고
    • Risk factors for doxorubicin-induced congestive heart failure
    • Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
    • (1979) Ann Intern Med , vol.91 , pp. 710-717
    • Von Hoff, D.D.1    Layard, M.W.2    Basa, P.3
  • 5
    • 0017354816 scopus 로고
    • Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases
    • Von Hoff D.D., Rozencweig M., Layard M., et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977, 62:200-208.
    • (1977) Am J Med , vol.62 , pp. 200-208
    • Von Hoff, D.D.1    Rozencweig, M.2    Layard, M.3
  • 6
    • 28744446343 scopus 로고    scopus 로고
    • ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the Interna
    • Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
    • (2005) Circulation , vol.112
    • Hunt, S.A.1    Abraham, W.T.2    Chin, M.H.3
  • 7
    • 0038521374 scopus 로고    scopus 로고
    • Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
    • Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
    • (2003) Cancer , vol.97 , pp. 2869-2879
    • Swain, S.M.1    Whaley, F.S.2    Ewer, M.S.3
  • 8
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 9
    • 0022622814 scopus 로고
    • Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy
    • Torti F.M., Bristow M.M., Lum B.L., et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986, 46:3722-3727.
    • (1986) Cancer Res , vol.46 , pp. 3722-3727
    • Torti, F.M.1    Bristow, M.M.2    Lum, B.L.3
  • 10
    • 0035985273 scopus 로고    scopus 로고
    • Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
    • Jensen B.V., Skovsgaard T., Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002, 13:699-709.
    • (2002) Ann Oncol , vol.13 , pp. 699-709
    • Jensen, B.V.1    Skovsgaard, T.2    Nielsen, S.L.3
  • 11
    • 0031734394 scopus 로고    scopus 로고
    • Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer
    • Ryberg M., Nielsen D., Skovsgaard T., et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998, 16:3502-3508.
    • (1998) J Clin Oncol , vol.16 , pp. 3502-3508
    • Ryberg, M.1    Nielsen, D.2    Skovsgaard, T.3
  • 12
    • 42749100219 scopus 로고    scopus 로고
    • Different anthracycline derivates for reducing cardiotoxicity in cancer patients
    • CD005006
    • van Dalen E.C., Michiels E.M., Caron H.N., et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2006, 4. CD005006.
    • (2006) Cochrane Database Syst Rev , vol.4
    • van Dalen, E.C.1    Michiels, E.M.2    Caron, H.N.3
  • 13
    • 0026042237 scopus 로고
    • A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors
    • Casper E.S., Gaynor J.J., Hajdu S.I., et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991, 68:1221-1229.
    • (1991) Cancer , vol.68 , pp. 1221-1229
    • Casper, E.S.1    Gaynor, J.J.2    Hajdu, S.I.3
  • 14
    • 42749107115 scopus 로고    scopus 로고
    • Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy
    • CD005008
    • van Dalen E.C., van der Pal H.J., Caron H.N., et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006, 4. CD005008.
    • (2006) Cochrane Database Syst Rev , vol.4
    • van Dalen, E.C.1    van der Pal, H.J.2    Caron, H.N.3
  • 15
    • 3042850886 scopus 로고    scopus 로고
    • The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
    • Lipshultz S.E., Rifai N., Dalton V.M., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351:145-153.
    • (2004) N Engl J Med , vol.351 , pp. 145-153
    • Lipshultz, S.E.1    Rifai, N.2    Dalton, V.M.3
  • 16
    • 80052044499 scopus 로고    scopus 로고
    • Cardioprotective interventions for cancer patients receiving anthracyclines
    • CD003917
    • van Dalen E.C., Caron H.N., Dickinson H.O., et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005, 1. CD003917.
    • (2005) Cochrane Database Syst Rev , vol.1
    • van Dalen, E.C.1    Caron, H.N.2    Dickinson, H.O.3
  • 17
    • 28044442932 scopus 로고    scopus 로고
    • Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
    • Nakamae H., Tsumura K., Terada Y., et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005, 104:2492-2498.
    • (2005) Cancer , vol.104 , pp. 2492-2498
    • Nakamae, H.1    Tsumura, K.2    Terada, Y.3
  • 18
    • 3042698689 scopus 로고    scopus 로고
    • Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults
    • Hequet O., Le Q.H., Moullet I., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004, 22:1864-1871.
    • (2004) J Clin Oncol , vol.22 , pp. 1864-1871
    • Hequet, O.1    Le, Q.H.2    Moullet, I.3
  • 19
    • 49249105457 scopus 로고    scopus 로고
    • Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma
    • Hershman D.L., McBride R.B., Eisenberger A., et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:3159-3165.
    • (2008) J Clin Oncol , vol.26 , pp. 3159-3165
    • Hershman, D.L.1    McBride, R.B.2    Eisenberger, A.3
  • 20
    • 0031792641 scopus 로고    scopus 로고
    • Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
    • Shapiro C.L., Hardenbergh P.H., Gelman R., et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998, 16:3493-3501.
    • (1998) J Clin Oncol , vol.16 , pp. 3493-3501
    • Shapiro, C.L.1    Hardenbergh, P.H.2    Gelman, R.3
  • 21
    • 0025850827 scopus 로고
    • Cardiac toxicity 4 to 20 years after completing anthracycline therapy
    • Steinherz L.J., Steinherz P.G., Tan C.T., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266:1672-1677.
    • (1991) JAMA , vol.266 , pp. 1672-1677
    • Steinherz, L.J.1    Steinherz, P.G.2    Tan, C.T.3
  • 22
    • 3342905435 scopus 로고    scopus 로고
    • Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy
    • Pein F., Sakiroglu O., Dahan M., et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004, 91:37-44.
    • (2004) Br J Cancer , vol.91 , pp. 37-44
    • Pein, F.1    Sakiroglu, O.2    Dahan, M.3
  • 23
    • 34548533485 scopus 로고    scopus 로고
    • Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
    • Pinder M.C., Duan Z., Goodwin J.S., et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25:3808-3815.
    • (2007) J Clin Oncol , vol.25 , pp. 3808-3815
    • Pinder, M.C.1    Duan, Z.2    Goodwin, J.S.3
  • 24
    • 32144448027 scopus 로고    scopus 로고
    • Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
    • Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
    • (2005) J Clin Oncol , vol.23 , pp. 7820-7826
    • Ewer, M.S.1    Vooletich, M.T.2    Durand, J.B.3
  • 25
    • 33748642331 scopus 로고    scopus 로고
    • Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
    • Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107-4115.
    • (2006) J Clin Oncol , vol.24 , pp. 4107-4115
    • Guarneri, V.1    Lenihan, D.J.2    Valero, V.3
  • 26
    • 34548152541 scopus 로고    scopus 로고
    • Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility
    • Telli M.L., Hunt S.A., Carlson R.W., et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007, 25:3525-3533.
    • (2007) J Clin Oncol , vol.25 , pp. 3525-3533
    • Telli, M.L.1    Hunt, S.A.2    Carlson, R.W.3
  • 27
    • 66249091930 scopus 로고    scopus 로고
    • The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine
    • Ross J.S., Slodkowska E.A., Symmans W.F., et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
    • (2009) Oncologist , vol.14 , pp. 320-368
    • Ross, J.S.1    Slodkowska, E.A.2    Symmans, W.F.3
  • 28
    • 0036099675 scopus 로고    scopus 로고
    • ErbB2 is essential in the prevention of dilated cardiomyopathy
    • Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
    • (2002) Nat Med , vol.8 , pp. 459-465
    • Crone, S.A.1    Zhao, Y.Y.2    Fan, L.3
  • 29
    • 0028884413 scopus 로고
    • Requirement for neuregulin receptor erbB2 in neural and cardiac development
    • Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378:394-398.
    • (1995) Nature , vol.378 , pp. 394-398
    • Lee, K.F.1    Simon, H.2    Chen, H.3
  • 30
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 31
    • 36849016904 scopus 로고    scopus 로고
    • Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→ paclitaxel (T) vs AC→ T with trastuzumab (H) Chicago, IL, [abstract]
    • Abstract LBA513
    • Rastogi P., Jeong J., Geyer C.E., et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→ paclitaxel (T) vs AC→ T with trastuzumab (H) Chicago, IL, [abstract]. J Clin Oncol 2007, 25(Suppl 1). Abstract LBA513.
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL 1
    • Rastogi, P.1    Jeong, J.2    Geyer, C.E.3
  • 32
    • 38149097872 scopus 로고    scopus 로고
    • Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America. Washington, DC, September 16-19, 2007
    • Mehra M.R., Rockman H.A., Greenberg B.H. Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America. Washington, DC, September 16-19, 2007. J Am Coll Cardiol 2008, 51:320-327.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 320-327
    • Mehra, M.R.1    Rockman, H.A.2    Greenberg, B.H.3
  • 33
    • 29744442709 scopus 로고    scopus 로고
    • Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
    • Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
    • (2005) J Clin Oncol , vol.23 , pp. 7811-7819
    • Tan-Chiu, E.1    Yothers, G.2    Romond, E.3
  • 34
    • 33845914783 scopus 로고    scopus 로고
    • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    • Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
    • (2007) Lancet , vol.369 , pp. 29-36
    • Smith, I.1    Procter, M.2    Gelber, R.D.3
  • 35
    • 34548531901 scopus 로고    scopus 로고
    • Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
    • Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
    • (2007) J Clin Oncol , vol.25 , pp. 3859-3865
    • Suter, T.M.1    Procter, M.2    van Veldhuisen, D.J.3
  • 36
    • 84857112700 scopus 로고    scopus 로고
    • BCIRG 006: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. 2006. Available at: Accessed January 14, 2009.
    • Slamon D, Eiermann W, Robert N, et-al. BCIRG 006: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. 2006. Available at: Accessed January 14, 2009. http://wwwbcirgorg/NR/rdonlyres/eqkdodg2dy7t557o7s6uvj7ytpe6gcfg5gmh2ely6hnhh5pjlabz3nd6jddlnao7qoikej3edohsijyiisfvp367uuc/BCIRG006%2b2nd%2bInterim%2bAnalysispdf.
    • Slamon, D.1    Eiermann, W.2    Robert, N.3
  • 37
    • 33645720799 scopus 로고    scopus 로고
    • Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide with docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study
    • Slamon D.J., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide with docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94:S5.
    • (2005) Breast Cancer Res Treat , vol.94
    • Slamon, D.J.1    Eiermann, W.2    Robert, N.3
  • 38
    • 34548481766 scopus 로고    scopus 로고
    • 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
    • de Korte M.A., de Vries E.G., Lub-de Hooge M.N., et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007, 43:2046-2051.
    • (2007) Eur J Cancer , vol.43 , pp. 2046-2051
    • de Korte, M.A.1    de Vries, E.G.2    Lub-de Hooge, M.N.3
  • 39
    • 33744831505 scopus 로고    scopus 로고
    • Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    • Perik P.J., Lub-De Hooge M.N., Gietema J.A., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
    • (2006) J Clin Oncol , vol.24 , pp. 2276-2282
    • Perik, P.J.1    Lub-De Hooge, M.N.2    Gietema, J.A.3
  • 40
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 41
    • 77949884661 scopus 로고    scopus 로고
    • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    • Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
    • (2010) J Clin Oncol , vol.28 , pp. 1124-1130
    • Blackwell, K.L.1    Burstein, H.J.2    Storniolo, A.M.3
  • 42
    • 73149115341 scopus 로고    scopus 로고
    • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    • Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
    • (2009) J Clin Oncol , vol.27 , pp. 5538-5546
    • Johnston, S.1    Pippen, J.2    Pivot, X.3
  • 43
    • 0035993035 scopus 로고    scopus 로고
    • Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy
    • Toko H., Oka T., Zou Y., et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002, 25:597-603.
    • (2002) Hypertens Res , vol.25 , pp. 597-603
    • Toko, H.1    Oka, T.2    Zou, Y.3
  • 44
    • 0042198675 scopus 로고    scopus 로고
    • B-type natriuretic peptide in cardiovascular disease
    • de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.
    • (2003) Lancet , vol.362 , pp. 316-322
    • de Lemos, J.A.1    McGuire, D.K.2    Drazner, M.H.3
  • 45
    • 0033822124 scopus 로고    scopus 로고
    • Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction
    • Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000, 21:1502-1513.
    • (2000) Eur Heart J , vol.21 , pp. 1502-1513
  • 46
    • 2942522528 scopus 로고    scopus 로고
    • Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
    • Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
    • (2004) Circulation , vol.109 , pp. 2749-2754
    • Cardinale, D.1    Sandri, M.T.2    Colombo, A.3
  • 47
    • 33845402341 scopus 로고    scopus 로고
    • Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
    • Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474-2481.
    • (2006) Circulation , vol.114 , pp. 2474-2481
    • Cardinale, D.1    Colombo, A.2    Sandri, M.T.3
  • 48
    • 33845206791 scopus 로고    scopus 로고
    • Protective effects of carvedilol against anthracycline-induced cardiomyopathy
    • Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48:2258-2262.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 2258-2262
    • Kalay, N.1    Basar, E.2    Ozdogru, I.3
  • 49
    • 15744395079 scopus 로고    scopus 로고
    • UK audit of left ventricular ejection fraction estimation from equilibrium ECG gated blood pool images
    • Skrypniuk J.V., Bailey D., Cosgriff P.S., et al. UK audit of left ventricular ejection fraction estimation from equilibrium ECG gated blood pool images. Nucl Med Commun 2005, 26:205-215.
    • (2005) Nucl Med Commun , vol.26 , pp. 205-215
    • Skrypniuk, J.V.1    Bailey, D.2    Cosgriff, P.S.3
  • 50
    • 0035370698 scopus 로고    scopus 로고
    • Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study
    • Wassmuth R., Lentzsch S., Erdbruegger U., et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J 2001, 141:1007-1013.
    • (2001) Am Heart J , vol.141 , pp. 1007-1013
    • Wassmuth, R.1    Lentzsch, S.2    Erdbruegger, U.3
  • 51
    • 33746849860 scopus 로고    scopus 로고
    • Troponin I and cardiovascular risk stratification in patients with testicular cancer
    • [author reply: 3508-9]
    • Cardinale D., Lamantia G., Cipolla C.M. Troponin I and cardiovascular risk stratification in patients with testicular cancer. J Clin Oncol 2006, 24:3508. [author reply: 3508-9].
    • (2006) J Clin Oncol , vol.24 , pp. 3508
    • Cardinale, D.1    Lamantia, G.2    Cipolla, C.M.3
  • 52
    • 0035985276 scopus 로고    scopus 로고
    • Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
    • Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13:710-715.
    • (2002) Ann Oncol , vol.13 , pp. 710-715
    • Cardinale, D.1    Sandri, M.T.2    Martinoni, A.3
  • 53
    • 0033855860 scopus 로고    scopus 로고
    • Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
    • Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36:517-522.
    • (2000) J Am Coll Cardiol , vol.36 , pp. 517-522
    • Cardinale, D.1    Sandri, M.T.2    Martinoni, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.